The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial ...

JERSEY CITY, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs ...

We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections. We have successfully launched two hospital ...

If I make it to the presidential palace, I will do just what I did as mayor. You drug pushers, hold-up men and do-nothings, you better go out. Because I'd kill you," he said during that campaign.

Lipid nanoparticles have emerged as leading candidates for encapsulating mRNA drugs and have shown success in in vivo applications. Here, the authors provide a step-by-step guide for mRNA lipid ...

Future Microbiol. 2013;8(8):967-978.

Too much of anything can be bad, and the consequence of too much of drugs is something we are all familiar with. Not all of us have tried these drugs, but cinema has shown us the most graphic and ...

Do you want to know how you can develop new drugs to combat drug-resistant microorganisms? How to find a way to imprint the immune system to increase tolerance? Reducing the side effects of treatment ...